Degradation of superparamagnetic iron oxide nanoparticle-induced ferritin by lysosomal cathepsins and related immune response

Nanomedicine

Volumn 7, Issue 5, 2012, Pages 705-717

  Laskar, Amit ^a   Ghosh, Moumita ^a   Khattak, Sikander Iqbal ^a   Li, Wei ^a   Yuan, Xi Ming ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

atherosclerosis; cytokine; degradation; iron; lysosomal; monocyte; nanoparticle

Indexed keywords

CATHEPSIN; DEFEROXAMINE; FERRITIN; FERROPORTIN; OXYSTEROL; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA;

CELL FUNCTION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOBLOTTING; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REVIEW; STAINING;

CATHEPSINS; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CONTRAST MEDIA; FERRIC COMPOUNDS; FERRITINS; FLOW CYTOMETRY; HUMANS; IMMUNITY, ACTIVE; LYSOSOMES; MAGNETITE NANOPARTICLES; MICROSCOPY, FLUORESCENCE; PROTEOLYSIS;

EID: 84861609579     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.148     Document Type: Review

References (40)

1. Lunov O, Syrovets T, Rocker C et al. Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. Biomaterials 31(34), 9015-9022 (2010).
2. Weinstein JS, Varallyay CG, Dosa E et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system infammatory pathologies, a review. J. Cereb. Blood Flow Metab. 30(1), 15-35 (2010).
3. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann. Biomed. Eng. 34(1), 23-38 (2006).
4. Yang CY, Hsiao JK, Tai MF et al. Direct labeling of hMSC with SPIO: the long-term infuence on toxicity, chondrogenic differentiation capacity, and intracellular distribution. Mol. Imaging Bio l.13 (3), 443-451 (2011).
5. Raschzok N, Muecke DA, Adonopoulou MK et al. In vitro evaluation of magnetic resonance imaging contrast agents for labeling human liver cells: implications for clinical translation. Mol. Imaging Biol. 13(4), 613-622 (2011).
6. Hsiao JK, Chu HH, Wang YH et al. Macrophage physiological function after superparamagnetic iron oxide labeling. NMR Biomed. 21(8), 820-829 (2008).
7. Yeh CH, Hsiao KJ, Wang JL, Sheu F. Immunological impact of magnetic nanoparticles (feurocarbotran) on murine peritoneal macrophages. J. Nanopart. Res. 12(1), 151-160 (2010).
8. Lunov O, Syrovets T, Buchele B et al. The effect of carboxydextran-coated superparamagnetic iron oxide nanoparticles on c-Jun N-terminal kinase-mediated apoptosis in human macrophages. Biomaterials 31(19), 5063-5071 (2010).
9. Mahmoudi M, Simchi A, Milani AS, Stroeve P. Cell toxicity of superparamagnetic iron oxide nanoparticles. J. Colloid Interface Sci. 336(2), 510-518 (2009).
10. Walker EM, Walker SM. Effects of iron overload on the immune system. Ann. Clin. Lab. Sci. 30(4), 354-365 (2000).
11. Yuan XM, Li W. Iron involvement in multiple signaling pathways of atherosclerosis: a revisited hypothesis. Curr. Med. Chem. 15(21), 2157-2172 (2008).
12. Bresgen N, Ohlenschlager I, Wacht N, Afazel S, Ladurner G, Eckl PM. Ferritin and FasL (CD95L) mediate density dependent apoptosis in primary rat hepatocytes. J. Cell Physiol. 217(3), 800-808 (2008).
13. Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim. Biophys. Acta. 1790(7), 589-599 (2009).
14. Conus S, Simon HU. Cathepsins and their involvement in immune responses. Swiss Med. Wkly 140, w13042 (2010).
15. Cengelli F, Voinesco F, Juillerat-Jeanneret L. Interaction of cationic ultrasmall superparamagnetic iron oxide nanoparticles with human melanoma cells. Nanomedicine (Lond). 5(7), 1075-1087 (2010).
16. Hansson GK, Jonasson L. The discovery of cellular immunity in the atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 29(11), 1714-1717 (2009).
17. Laufer EM, Winkens MH, Narula J, Hofstra L. Molecular imaging of macrophage cell death for the assessment of plaque vulnerability Arterioscler. Thromb. Vasc. Biol. 29(7), 1031-1038 (2009).
18. Libby P, Dicarli M, Weissleder R. The vascular biology of atherosclerosis and imaging targets. J. Nucl. Med. 51(Suppl. 1), 33S-37S (2010).
19. Schmitz SA, Coupland SE, Gust R et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest. Radiol. 35(8), 460-471 (2000). (Pubitemid 30622013)
20. Schmitz SA, Taupitz M, Wagner S, Wolf KJ, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J. Magn. Reson. Imaging 14(4), 355-361 (2001). (Pubitemid 32906552)
21. Tang TY, Muller KH, Graves MJ et al. Iron oxide particles for atheroma imaging. Arterioscler. Thromb. Vasc. Biol. 29(7), 1001-1008 (2009).
22. Garcia-Cruset S, Carpenter KL, Guardiola F, Stein BK, Mitchinson MJ. Oxysterol profles of normal human arteries, fatty streaks and advanced lesions. Free Radic. Res. 35(1), 31-41 (2001). (Pubitemid 32725623)
23. Hulten LM, Lindmark H, Diczfalusy U et al. Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages. J. Clin. Invest. 97(2), 461-468 (1996).
24. Li W, Dalen H, Eaton JW, Yuan XM. Apoptotic death of infammatory cells in human atheroma. Arterioscler. Thromb. Vasc. Biol. 21(7), 1124-1130 (2001). (Pubitemid 34215139)
25. Recalcati S, Taramelli D, Conte D, Cairo G. Nitric oxide-mediated induction of ferritin synthesis in J774 macrophages by infammatory cytokines: role of selective iron regulatory protein-2 down regulation. Blood 91(3), 1059-1066 (1998). (Pubitemid 28078311)
26. Persson HL, Vainikka LK. Lysosomal iron in pulmonary alveolar proteinosis: a case report. Eur. Respir. J. 33(3), 673-679 (2009).
27. Ogawa Y, Kobayashi T, Kariya S et al. Prevention of hydrogen peroxide-induced apoptosis of human peripheral T cells by a lysosomotropic iron chelator, ammonium chloride. Int. J. Mol. Med. 14(6), 1007-1013 (2004).
28. Li W, Kornmark L, Jonasson L, Forssell C, Yuan XM. Cathepsin L is signifcantly associated with apoptosis and plaque destabilization in human atherosclerosis. Atherosclerosis 202(1), 92-102 (2009).
29. De Domenico I, Ward DM, Kaplan J. Specifc iron chelators determine the route of ferritin degradation. Blood 114(20), 4546-4551 (2009).
30. Kidane TZ, Sauble E, Linder MC. Release of iron from ferritin requires lysosomal activity Am. J. Physiol. Cell Physiol. 291(3), C445-C455 (2006). (Pubitemid 44343627)
31. Zhang Y, Mikhael M, Xu D et al. Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit. Antioxid. Redox Signal. 13(7), 999-1009 (2010).
32. De Domenico I, Vaughn MB, Li L et al. Ferroportin-mediated mobilization of ferritin iron precedes ferritin degradation by the proteasome. EMBO J. 25(22), 5396-5404 (2006). (Pubitemid 44764148)
33. Punnonen EL, Autio S, Marjomaki VS, Reunanen H. Autophagy, cathepsin L transport, and acidifcation in cultured rat fbroblasts. J. Histochem. Cytochem. 40(10), 1579-1587 (1992).
34. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24(8), 1359-1366 (2004). (Pubitemid 39056073)
35. Aydemir F, Jenkitkasemwong S, Gulec S, Knutson MD. Iron loading increases ferroportin heterogeneous nuclear RNA and mRNA levels in murine J774 macrophages. J. Nutr. 139(3), 434-438 (2009).
36. Knutson MD, Vafa MR, Haile DJ, Wessling-Resnick M. Iron loading and erythrophagocytosis increase ferroportin 1 (FPN1) expression in J774 macrophages. Blood 102(12), 4191-4197 (2003). (Pubitemid 37487007)
37. Yuan XM, Li W, Baird SK, Carlsson M, Melefors O. Secretion of ferritin by iron-laden macrophages and infuence of lipoproteins. Free Radic. Res. 38(10), 1133-1142 (2004). (Pubitemid 39504349)
38. Ganz T. Cellular iron: ferroportin is the only way out. Cell Metab. 1(3), 155-157 (2005). (Pubitemid 43960605)
39. Cohen LA, Gutierrez L, Weiss A et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 116(9), 1574-1584 (2010).
40. Gray CP, Franco AV, Arosio P, Hersey P. Immunosuppressive effects of melanoma-derived heavy-chain ferritin are dependent on stimulation of IL-10 production. Int. J. Cancer 92(6), 843-850 (2001). (Pubitemid 32467374)